Showing results (171-180 of 203) with videos related to

Sort By:
Pageof 21
Annals of the Rheumatic Diseases|March 21, 2013
N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR)Hoda Mirjafari, Paul Welsh, Suzanne M M Verstappen, et al.
The Journal of Investigative Dermatology|October 22, 2017
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Zenas Z N Yiu, Catherine H Smith, Darren M Ashcroft, et al.
The Journal of Investigative Dermatology|October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
Annals of the Rheumatic Diseases|March 19, 2013
Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register--the EPIC-2-NOAR Study)Manjari Lahiri, Robert N Luben, Catharine Morgan, et al.
Clinical and Experimental Dermatology|May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohortOras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
Pharmacoepidemiology and Drug Safety|April 19, 2018
Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studiesStephen R Pye, Thérèse Sheppard, Rebecca M Joseph, et al.
The Journal of Rheumatology|December 18, 2012
Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damageSebastien Viatte, Darren Plant, Mark Lunt, et al.
Annals of the Rheumatic Diseases|December 22, 2012
Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritisFlora McErlane, Michael W Beresford, Eileen M Baildam, et al.
Endocrinology, Diabetes & Metabolism|July 12, 2019
Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetesNagaraj S Malipatil, Ghasem Yadegarfar, Mark Lunt, et al.
Pageof 21